Company intelligence / Profile preview
JD Bioscience
Beijing, Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
JD Bioscience is a clinical-stage biopharmaceutical company focused on the development of innovative small molecule therapies for metabolic and fibrotic diseases. Its lead program, JD-101, is a liver-targeted AMPK activator being evaluated in Phase 2 clinical trials for non-alcoholic steatohepatitis (NASH).
- Therapeutic areas
- EndocrinologyGastroenterologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences
Beyond the preview
Go deeper on JD Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JD Bioscience.